Following the release of two reports earlier this month, the U.S. Government Accountability Office (GAO) recently published a third report on PEPFAR. The report examines how PEPFAR “has worked with U.S. implementing agencies, international donors, and partner countries to increase the efficiency and reliability of antiretroviral (ARV) drug supply chains,” but it notes that “[e]valuations of partner-country supply chains reflect weaknesses in inventory controls and record keeping, which may increase the risk of drug shortages, waste, and loss,” the report summary states. GAO recommends “[t]he Secretary of State should direct OGAC to require country teams to (1) develop and implement plans to help partner countries improve inventory controls and record keeping; and (2) track the progress partner countries are making in measuring ARV drug consumption, waste, and loss,” according to the summary (5/28). The Center for Global Health Policy’s “Science Speaks” blog examines the report (Barton, 5/29).